# The untapped health and climate potential of cycling in France: a national assessment from individual travel data

Emilie Schwarz<sup>1</sup>, Marion Leroutier<sup>2</sup>, Audrey De Nazelle<sup>3,4</sup>, Philippe Quirion<sup>5</sup>, Kévin Jean<sup>1,6\*</sup>

<sup>1</sup>Laboratoire MESuRS, Conservatoire national des arts et métiers, Paris, France

<sup>2</sup>Misum, Stockholm School of Economics, Stockholm, Sweden

<sup>3</sup>Centre for Environmental Policy Imperial College London, London, United Kingdom,

<sup>4</sup>MRC Centre for Environment and Health, School of Public Health, Imperial College London, London, United Kingdom

<sup>5</sup>Centre International de Recherche sur l'Environnement et le Développement (CIRED), Centre National de la Recherche Scientifique, (CNRS), Nogent-sur-Marne, France,

<sup>6</sup>Unité PACRI, Institut Pasteur, Conservatoire national des arts et métiers, Paris, France.

\*<u>Corresponding author</u> : Kévin JEAN, Laboratoire MESuRS, Conservatoire national des arts et métiers, 75003, Paris, France. <u>Kevin.jean@lecnam.net</u>; Phone number: +33 140272569

<u>Keywords</u> : physical activity; cycling; health impact assessment; active transportation; health co-benefits of climate action; urban mobility

# ABSTRACT

#### Background

Promoting active modes of transportation such as cycling may generate important public health, economic, and climate mitigation benefits. We aim to assess mortality and morbidity impacts of cycling in a country with relatively low levels of cycling, France, along with associated monetary benefits; we further assess the potential additional benefits of shifting a portion of short trips from cars to bikes, including projected greenhouse gas emissions savings.

#### Methods

Using individual data from a nationally-representative mobility survey, we described the French 2019 cycling levels by age and sex. We conducted a burden of disease analysis to assess the incidence of five chronic diseases (breast cancer, colon cancer, cardio-vascular diseases, dementia, and type-2 diabetes) and numbers of deaths prevented by cycling. We assessed the corresponding direct medical cost savings and the intangible costs prevented based on the value of a statistical life year. Lastly, based on individual simulations, we assessed the likely additional benefits of shifting 25% of short (<10km) car trips were shifted to cycling.

#### Findings

The French adult (20-89 years) population was estimated to cycle on average of 1min 17sec pers<sup>-1</sup>.day<sup>-1</sup> in 2019, with important heterogeneity across gender and age. This yielded benefits of 1,919 (uncertainty interval, UI: 1,101-2,736) premature deaths and 5,963 (UI: 3,178-8,749) chronic disease cases prevented, with males enjoying nearly 75% of these benefits. Direct medical costs prevented were estimated at €191 million (UI: 98-285) annually, while the corresponding intangible costs were nearly 25 times higher (€4.8 billion, UI: 3.0-6.5). We estimated that in average, €1.02 (UI: 0.59-1.62) of intangible costs were prevented for every km cycled. Shifting 25% of short car trips to biking would yield approximatively a 3-fold increase in benefits, while also generating important CO<sub>2</sub> emission reductions (0.688 MtCO2e, UI: 0.524-0.854).

#### Interpretation

In a country of low- to moderate cycling culture, cycling already generates important public health and health-related economic benefits. Further development of active transportation would increase these benefits while also contributing to climate change mitigation targets.

#### Funding

This research received no specific grant from any funding agency in the public, commercial, or not-forprofit sectors.

Insufficient physical activity is responsible for a substantial global burden, with an approximatively 7% of all-cause deaths attributable. This burden is even more pronounced in Europe, with an approximate 10% of all-cause deaths and 30% of direct health-care costs of non-communicable diseases and mental health conditions attributable to physical inactivity <sup>1,2</sup>. In high-income Western countries, the prevalence of physical activity reaches more than 40% while showing no decreasing trends over time <sup>3</sup>. While the disquieting situation results in part from individual behaviors and choices, collective and societal decisions bear an essential responsibility, especially with regards to transport-related physical activity <sup>4</sup>. Active travel offers a unique opportunity to boost physical activity by encouraging seamless integration in daily activities, requiring little to no additional time commitments and costs to the individual <sup>5</sup>. Despite clear benefits of the promotion of utilitarian cycling, most countries do not use it to its full potential: in temperate regions such as the UK or France, the modal share of cycling remains below 3%, far from the 15 to 27% rates obtained in countries such as the Netherlands or Denmark <sup>6,7</sup>.

Collective choices regarding mobility also largely contribute to climate change, which is widely recognized as one the biggest public health issues of the upcoming decades<sup>8</sup>. In Europe, the transportation sector represents the second largest contributor of greenhouse gas emissions<sup>9</sup>, and the first in France where it accounts for 31% of the national emissions, among which approximately 50% are attributable to cars<sup>10</sup>. Therefore, promoting modal shift from cars to active transportation, such as cycling, represents a relevant response to both the public health burden of physical inactivity and the urgent need to cut down emissions.

While the public health benefits of cycling have already been assessed in a large variety of contexts <sup>11</sup>, national assessments based on representative mobility data are less common <sup>12</sup>. Moreover, few burden of disease studies have assessed its impact in terms of both mortality and morbidity or have estimated the associated direct medical and intangible costs avoided <sup>13,14</sup>. Such assessments can contribute meaningfully to intense debates currently ongoing about the future of mobility in a context of ambitious decarbonisation targets and energy crises in many high-income Western countries such as France.

Our aim in this study was to demonstrate how cycling can contribute to health promotion in a Western country with relatively low cycling rates. We first assessed the benefits associated with current cycling levels in France in terms of prevented mortality and morbidity, based on nationally-representative individual mobility data from 2019. Secondly, we assessed the benefits that could be associated with shifting a portion of short trips currently made by car to bike trips.

# **MATERIALS AND METHODS**

#### Mobility data

Individual-level mobility data were accessed from the 2019 *Enquête mobilité des personnes* ("People's mobility survey") <sup>15</sup>. This survey is conducted every 10 years and the most recent data represents the mobility of the metropolitan French population in 2019, before the onset of the Covid-19 pandemic. 13,825 individuals aged 5 years and older were asked face to face about their travels the day before. Distances travelled are consolidated using geographic information systems, based on reported departure and arrival location. The sampling design and sampling weights ensure that the survey is representative of travel behaviours across weekdays and weekends in France. We analyzed all cycling trips, regardless of travel purpose and week day. Distances cycled were converted into exposure time (i.e. minutes of cycling per day) considering an average cycling speed of 14.9 km.h<sup>-1</sup> <sup>16</sup>. As e-bikes were

not frequently used in 2019, for simplicity, we assumed the same speed and metabolic equivalent of task (MET) values for e-bikes than for classical bikes.

#### Morbi-mortality and demographic data

Based on a previous systematic review <sup>17</sup>, we assumed a protective effect of physical activity on the following five diseases: breast cancer in females, colon cancer, cardiovascular disease, dementia, and type 2 diabetes <sup>18–22</sup>. We also assumed a protective effect of cycling on all-cause mortality as documented by the meta-analysis by Kelly et al <sup>23</sup>. As this meta-analysis considered all-cause mortality, potential increases in exposure to air pollution or injury are implicitly controlled. We thereafter use the term "morbi-mortality" to refer to these five chronic diseases and all-cause mortality. For each morbi-mortality event, the relative risk (RR) identified in the literature was scaled for a reference volume of 11.25 MET.hours (supplementary Table 1).

France-specific incident cases for cardiovascular disease, dementia, and type 2 diabetes were determined for the year 2018 from a database of new beneficiaries of long-term illness coverage (*Affectations Longues Durées*, ALD) by the French National health insurance system, using the most recent data available. The 2019 incidence data for breast cancer and colon cancer were taken from the French National Cancer Institute. Deaths, death rates, life-expectancy and population count estimates for 2019 were taken from the National Institute of Statistics and Economic Studie <sup>24</sup>. (Table 1).

# Health impact modelling

The health benefits of 2019 levels of cycling were assessed compared to a counterfactual "zero cycling" scenario in which trips did not entail any physical activity.

For each individual surveyed, time exposure to cycling (if any) was converted into a percentage reduction in the age-specific risk for each morbi-mortality event. Therefore, for each event, we estimated the reduced individual risk attributable to cycling as compared to the zero cycling counterfactual scenario. Following the Health Economic Assessment Tool (HEAT) approach, we assumed linear dose-response functions (DRF) for the mortality and morbidity effects of cycling while disregarding baseline levels of physical activity, and we capped the all-cause mortality reduction at 45% <sup>25</sup>. The age range considered for reductions in morbidity and mortality was 20-89 years. We disregarded younger and older ages because of the scarcity of evidence for the health effects of physical activity in these age ranges for these specific outcomes. For each morbi-mortality event, by summing up the reduction in individual probability of event across the study sample, we estimated the total number of events that have been averted by cycling. Survey weights were applied in the calculation in order to obtain nationally representative figures across weekdays and weekends.

# Burden of Disease

Based on the estimated age-specific numbers of morbi-mortality events prevented, we estimated the corresponding Disability-Adjusted Life Years (DALY) prevented by adding up the years of life lost (YLL) and the years lived with disability (YLD). To calculate YLD, for each of the five morbidity event, we estimated an average disability weight by dividing disease-specific YLD-estimates by disease-specific prevalence estimates obtained from the 2019 Global Burden of Disease (GBD) <sup>26</sup>, based on the method described in <sup>27</sup>.

# Health economic evaluation

We evaluated the monetarized benefits of 2019 French cycling levels by considering two different definitions of costs. We first estimated the *medical costs* associated with chronic diseases included in the analyses. Disease-specific medical costs were extracted from a recent French governmental report

on the assessment of health impacts of public investments and were expressed in Euros 2018 (Table)<sup>27</sup>. However, such evaluation of the tangible medical costs prevented by cycling does not include the benefits on mortality. Therefore, we also estimated the intangible costs prevented by cycling using the standard value of statistical life year (VSLY) that is recommended in France for the socioeconomic evaluation of public investments<sup>28</sup>. Estimates of intangible costs prevented by cycling thus rely on the VSLY of 133k€, expressed in Euros 2019.

#### Uncertainty analysis

Central values and 95% confidence intervals for cycling exposure were estimated while accounting for the survey sampling design and weights using the R package *survey*<sup>29</sup>.

Uncertainty surrounding the RR relating cycling and morbi-mortality events were characterized by a lognormal distribution constructed for each outcome based on the RR central values and the lower and upper bounds of the 95% confidence interval provided in the literature. We then combined the uncertainties using a Monte Carlo approach where we independently sampled a RR value for each morbi-mortality event. We randomly sampled 1000 combinations of RR values. Based on a given set of randomly-sampled RR values, the mean value and the standard-error for each outcome were estimated and results were combined across sets of RR combinations using the Rubin's rule <sup>30</sup>. The distributions corresponding to each of the 100 replications were then combined together to generate a posterior distribution for each outcome, from which we computed the 2.5% and 97.5% percentiles to obtain 95% uncertainty intervals (UI).

# Modal shift scenario

Lastly, based on individual-level simulations, we assessed the potential additional public health benefits associated with a modal shift scenario in which 25% of car trips less than 10km would be shifted to cycling. To do so, we randomly selected 25% of respondents reporting such car trips, while also reporting no cycling trips, and estimated the corresponding exposure time to cycling had these trips been cycled. We then re-conducted the steps of the HIA described above to assess the health and health-related economic benefits associated, while assuming no substitution effect of cycling on other types of physical activity. We performed 100 random draws of car trips to be re-allocated to bike trips. For each of these random selections, we computed the DALY prevented together with the 95% UI following the steps previously described. Results of each replication were combined to generate a posterior distribution for each outcome and compute 95% UI. Lastly, we estimated the CO<sub>2</sub> emissions averted in this modal shift scenario, assuming that the 2019 French car fleet emitted on average 124  $gCO_2.km^{-1}$  <sup>31</sup>.

# RESULTS

In 2019, among the French population of 20-89 year-olds (population size, 49.0 million), the cumulative kilometers biked in France added up to 4.64 (95% CI: 3.28-6.00) billion kilometers, of which 6.23% were cycled on e-bikes. This represented a per-capita average distance biked of 0.32 (95% CI: 0.27-0.37) km.pers<sup>-1</sup>.day<sup>-1</sup>, corresponding to an average exposure time of 1min 17sec pers<sup>-1</sup>.day<sup>-1</sup>. The proportion of the population reporting any cycling trip on a given day, accounting for differences in weekends and weekdays, was 3.12% (95% CI: 2.64-3.61%), with variations according to age and sex (Figure 1). In all age

groups, the proportion of cyclist was higher in males vs. females, and the average distance cycled among cyclists was higher in male vs. female. This resulted in 72.2% (95% CI: 60.7%-82.6%) of all cycling distances being biked by males.

# Health impact assessment

Based on the observed cycling levels, we estimated that 1,919 (UI: 1,101-2,736) premature deaths and 5,963 (UI: 3,178-8,749) chronic diseases were prevented in 2019 in France due the protective effect of biking physical activity. The chronic disease with the greatest number of cases prevented was type-2 diabetes (n=3,743, UI: 1,576-5,912), 3743.838 followed by CVD (n=1,578, UI: 778-2,378). Of all morbimortality events prevented, 74.9% benefited males (Figure 2). On average, cycling reduced the yearly mortality for the total adult population by 0.68% (UI: 0.47% - 0.87%).

We further estimated that overall, 35,135 DALYs (UI: 22,693 – 48,791) were prevented through cyclingrelated physical activity, of which 28,416 (80.9%) were driven by mortality (YLL) and 6,719 (19.1%) by morbidity (YLD) (Figure 3). Based on the average values of annual medical costs associated with each chronic disease considered here, we estimated that the 2019 levels of cycling saved €191 (UI: 98-285) million annual medical (tangible) costs. Based on the value of a statistical life year, combining intangible costs of mortality and morbidity, we estimated that cycling prevented €4.75 (UI: 3.02-6.49) billion, roughly 25 times the annual medical (tangible) costs. When related to the total kilometers traveled, this led to the estimate that each kilometer traveled by bike avoids an average of €1.02 (UI: 0.59-1.62) of intangible costs. Table 2 summarizes the burden and costs prevented for each morbi-mortality event.

# Modal shift scenarios

The proportion of survey participants reporting any short (<10km) car trip on a given day was 41.2% (95% CI: 37.5-44.8) overall and was quite homogeneously distributed across age and sex, as was the mean length of these short car trips (3.69 km, 95% CI: 3.57-3.81) (Supplementary Figure 1).

Shifting 25% of short car trip to cycling would generate an additional 5.550 billion km cycled (UI: 4.222-6.884), ie an approximate 20% higher cycling exposure compared to the 2019 baseline. Due to the age distribution of drivers, this would translate into approximately 2.6 times more deaths prevented compared to the 2019 cycling levels (4,707 deaths prevented, UI: 2,865-7,199) (Table 3). This modal shift scenario would prevent  $\notin$ 7.476 billions in terms of intangible costs (UI: 4.970-10.71), while also reducing CO<sub>2</sub> emissions by 0.688 mega-tons (UI: 0.524-0.854).

# DISCUSSION

In this study relying on a nationally-representative mobility survey, we show that, despite relatively low levels of cycling in France in 2019, physical activity due to cycling generated important public health benefits in terms of morbidity and mortality alleviated. These benefits were unequally distributed across sex, reflecting the cycling distribution, with males benefiting nearly 75% of the morbi-mortality events prevented. Of the 5 different chronic diseases considered, cycling levels mostly prevented cases of diabetes and CVD, and in all prevented €187 million in direct medical costs in 2019. Most of the public health benefits of cycling, however, resided in the mortality alleviated, which corresponded to approximately 80% of all DALY associated with cycling. When accounting for the VSLY, we estimate that the physical activity linked to the 2019 levels of cycling prevented nearly €5 billion of intangible costs annually. This corresponds to an approximate 1€ prevented for every km cycled. The prevented

intangible costs associated with mortality largely outweighed the prevented direct medical costs linked to alleviated morbidity, at an approximate ratio of 25:1. Furthermore, we showed that more than twice as many deaths could be further prevented, with a modest modal shift of 25% short car trips to cycling, which would also lead to sizeable  $CO_2$  emissions reduction. These results confirm the relevance of promoting cycling both for planetary and public health.

Results from the 2019 wave of the French transport survey show that France remains within the countries with a low cycling culture <sup>32</sup>. The French adult population reported cycling on average less than 10 minutes per week, which is low compared to the more than 70 minutes per week reported by the Dutch adult population <sup>12</sup>. Despite repeated calls to decrease motorized trips to help tackle climate change and physical inactivity, cycling mode share for France remained at about 2.7% of all trips in France between 2008, the year of the previous wave of travel survey, and 2019. The bike modal remained the same (2.7%) between the two waves (7). This explains the relatively low levels of the health benefits of cycling in France as compared to other countries. In France, we estimate that cycling reduces the mortality risk by 0.6%, compared to 7.4% in the Netherlands <sup>12</sup>. We showed that currently males are the main beneficiaries of cycling health benefits in France because they represent a large fraction of the cyclists. However, previous surveys have shown that females are equally represented in countries where cycling is normalized, providing an additional motivation for cycling promotion <sup>33</sup>.

Our burden of disease approach allowed us to estimate the relative contribution of mortality and morbidity alleviated in the total health benefits of cycling. We found that cycling would prevent nearly 3 times more chronic diseases than deaths (approximatively 5,900 diseases and 1,800 deaths). This ratio was similar to the one reported in a previous HIA in Barcelona<sup>17,34</sup>. However, the chronic conditions prevented are associated with relatively low disability weights (ranging between 0.05 and 0.15), which explains the large contribution of prevented mortality in the DALY. In terms of morbidity, we showed that the disease most frequently prevented were diabetes and cardio-vascular diseases. Previous studies reported that cycling also contributes to reducing mortality among adults with diabetes<sup>35</sup>, making it a relevant intervention for both primary and secondary prevention.

Our health economic evaluation, which relied on nationally recommended monetarization values for the socio-economic evaluation of public investments, we show that current cycling practices already prevent nearly  $\in$ 5 billion in intangible costs annually. This represents an approximate  $\in$ 1 prevented for every kilometer cycled. This unit value is of a similar order of magnitude to those reported in other return on investment studies. For instance, in Queensland, Australia, it was reported to be AUD 0.67 (approximately  $\in$ 0.4) per kilometer ridden.<sup>36</sup> Such substantial monetized health benefits associated with cycling contribute to building a strong case for significant investment in cycling.

We further estimated the public and climate mitigation benefits of a modal shift scenario. We estimated that shifting a quarter of short car trips to cycling would further prevent approximately 4,700 annual deaths and avoid  $\xi$ 7.5 billion intangible costs. Table 4 further presents a broad comparison of elements to put into context the results of the modal shifts scenarios we assessed here. As a rough comparison, this is triple the number of deaths avoided due to efforts in road safety made in France over the past 10 years, which represented a public investment of more than  $\xi$ 3.5 billion a year <sup>37</sup>. From a climate change perspective, shifting 25% of short car trips to cycling would yield roughly half of CO<sub>2</sub> emission reductions of a measure that has been publicly debated in France in the context of the 2022 energy crisis: reducing the maximal speed on highway from 130 to 110 km/h <sup>38</sup>. However, it is also important to note that investments to foster active mobility may possibly result in large additional indirect cuts in CO<sub>2</sub>

emissions, for instance through encouraging multi-modal trips and/or re-location of activities which would reduce global distances travelled.

Our study suffers from several limitations. First, we disregarded the baseline levels of physical activity when assessing the health benefits of existing or projected levels of cycling. However, the DRF we used came from meta-analyses of studies conducted in samples of participants with heterogeneous levels of physical activity. Second, we did not account for the reduced physical activity that e-bikes may represent as compared to regular bikes. However, e-bikes only contributed to 6% of the distances we considered, suggesting a modest over-estimate of the benefits we document. Similarly, the modal shift scenarios we assessed did not account for a possible compensation during non-transport physical activity which could reduce the benefits we assessed. However, the existing evidence suggests that such substitution effect is unlikely or limited, in healthy adults at least <sup>41,42</sup>. On the other hand, the dose-response relationship we used for all-cause mortality may be considered as conservative, as a more recent meta-analysis suggested a substantially more beneficial dose-response relationship <sup>43</sup>. In a previous assessment, the choice of this dose-response relationship was identified as the main source of sensitivity in the estimates <sup>44</sup>.

This study is one of the few to assess the benefits of cycling at the country level based on detailed individual transportation data and, to our knowledge, the first to do so for France. One of its main strengths lies in the fact that it documents both the medical and the social costs prevented by cycling. Although they disregard a major part of the estimated health benefits (those related to the mortality alleviated), medical costs represent tangible costs effectively saved for collective benefit. On the other hand, social costs based on VSLY are intangible, because they represent the propensity of society to pay for the corresponding health benefits, but capture much more comprehensively the benefits expected from specific policies. The ratio of 1:25 we document here for these tangible and intangible costs may be useful to make sense of these figures in similar assessments.

The present study contributes to highlight the public health and climate mitigation benefits expected from the development of active transportation <sup>44,45</sup>. Our results suggest that public investments to encourage modal shift toward cycling may translate into important climate, health and health-related economic benefits, which are likely to exceed the costs implied <sup>46</sup>. Recently, due to the Covid-19 impact on public transportation, some local authorities have rapidly incentivized cycling by rolling out pop-up bike lanes. This resulted in a large short-term increase in cycling, including in France <sup>47</sup>. Commitment of national and local authorities is critical to sustaining these changes and the contribution of cycling to public and planetary health.

# **Consent for publication**

All authors have approved the manuscript and gave their consent for submission and publication.

# Availability of data and material

Individual-level mobility data were accessed from the 2019 Enquête mobilité des personnes ("French People's mobility survey") at: <u>https://www.statistiques.developpement-durable.gouv.fr/resultats-detailles-de-lenquete-mobilite-des-personnes-de-2019</u> [accessed April 5<sup>th</sup> 2023.]. All data produced in the present study are available upon reasonable request to the authors.

#### Ethics approval and consent to participate

Ethics approval and consent to participate have been collected by the institution in charge of the carrying out the survey: Ministère de la Transition écologique et de la Cohésion des territoires, Commissariat général au développement durable, Service des données et études statistiques (SDES) Sous-direction des statistiques des transports. The survey complies with all the standards of confidentiality of human data collection. More details here: https://www.statistiques.developpement-durable.gouv.fr/enquete-sur-la-mobilite-des-personnes-2018-2019?list-enquete=true

# **Competing interests**

The authors declare that they have no competing interests.

# Authors' contributions

ES, PQ, and KJ conceived the original idea. ML extracted and compiled input data. ES and KJ conducted the analysis and produced output figures and tables. ES, MS, AND, PQ, and KJ interpreted the results. ES and KJ wrote the first draft of the article. All authors provided critical feedback and helped shape the research, analysis and manuscript.

# REFERENCES

- 1 Katzmarzyk PT, Friedenreich C, Shiroma EJ, Lee I-M. Physical inactivity and non-communicable disease burden in low-income, middle-income and high-income countries. *Br J Sports Med* 2021; : bjsports-2020-103640.
- 2 Santos AC, Willumsen J, Meheus F, Ilbawi A, Bull FC. The cost of inaction on physical inactivity to public health-care systems: a population-attributable fraction analysis. *Lancet Glob Health* 2023; **11**: e32–9.
- 3 Guthold R, Stevens GA, Riley LM, Bull FC. Worldwide trends in insufficient physical activity from 2001 to 2016: a pooled analysis of 358 population-based surveys with 1.9 million participants. *Lancet Glob Health* 2018; **6**: e1077–86.
- 4 Koohsari MJ, Badland H, Giles-Corti B. (Re)Designing the built environment to support physical activity: Bringing public health back into urban design and planning. *Cities* 2013; **35**: 294–8.
- 5 WHO Regional Office for Europe. Walking and cycling: latest evidence to support policy-making and practice. Copenhagen, Denmark, 2022 https://www.who.int/europe/publications/i/item/9789289057882 (accessed April 4, 2023).
- 6 Nielsen TAS, Mulalic I, Christiansen H. Drivers of Cycling Mode-share: Analysis of Danes Travel Behavior 1996-2013. *Transp Res Procedia* 2016; **14**: 2284–8.

- 7 Goel R, Goodman A, Aldred R, *et al.* Cycling behaviour in 17 countries across 6 continents: levels of cycling, who cycles, for what purpose, and how far? *Transp Rev* 2021; **0**: 1–24.
- 8 Atwoli L, Baqui AH, Benfield T, *et al.* Call for emergency action to limit global temperature increases, restore biodiversity, and protect health. *BMJ* 2021; **374**: n1734.
- 9 European Environment Agency. Annual European Union greenhouse gas inventory 1990–2018 and inventory report 2020. Copenhagen, Denmark: European Environment Agency, 2020 https://www.eea.europa.eu//publications/european-union-greenhouse-gas-inventory-2020 (accessed Jan 14, 2022).
- 10 The High Council on Climate (HCC). Renforcer l'atténuation, engager l'adaptation [Reinforce mitigation, engage adaptation]. Paris, France, 2021 https://www.hautconseilclimat.fr/publications/rapport-annuel-2021-renforcer-lattenuation-engagerladaptation/ (accessed Jan 14, 2022).
- 11 Mueller N, Rojas-Rueda D, Cole-Hunter T, *et al.* Health impact assessment of active transportation: A systematic review. *Prev Med* 2015; **76**: 103–14.
- 12 Fishman E, Schepers P, Kamphuis CBM. Dutch Cycling: Quantifying the Health and Related Economic Benefits. *Am J Public Health* 2015; **105**: e13-15.
- 13 Woodcock J, Givoni M, Morgan AS. Health Impact Modelling of Active Travel Visions for England and Wales Using an Integrated Transport and Health Impact Modelling Tool (ITHIM). *PLOS ONE* 2013; **8**: e51462.
- 14 Mizdrak A, Blakely T, Cleghorn CL, Cobiac LJ. Potential of active transport to improve health, reduce healthcare costs, and reduce greenhouse gas emissions: A modelling study. *PLOS ONE* 2019; **14**: e0219316.
- 15 Service de la donnée et des études statistiques (SDES). Résultats détaillés de l'enquête mobilité des personnes 2019. Données Études Stat. Pour Chang. Clim. Lénergie Environ. Logement Transp. https://www.statistiques.developpement-durable.gouv.fr/resultats-detailles-de-lenquete-mobilite-des-personnes-de-2019 (accessed March 17, 2022).
- 16 Egiguren J, Nieuwenhuijsen MJ, Rojas-Rueda D. Premature Mortality of 2050 High Bike Use Scenarios in 17 Countries. *Environ Health Perspect* 2021; **129**: 127002.
- 17 Rojas-Rueda D, de Nazelle A, Teixidó O, Nieuwenhuijsen MJ. Health impact assessment of increasing public transport and cycling use in Barcelona: a morbidity and burden of disease approach. *Prev Med* 2013; **57**: 573–9.
- 18 Monninkhof EM, Elias SG, Vlems FA, *et al.* Physical Activity and Breast Cancer: A Systematic Review. *Epidemiology* 2007; **18**: 137.
- 19 Harriss DJ, Atkinson G, Batterham A, *et al.* Lifestyle factors and colorectal cancer risk (2): a systematic review and meta-analysis of associations with leisure-time physical activity. *Colorectal Dis* 2009; **11**: 689–701.

- 20 Hamer M, Chida Y. Walking and primary prevention: a meta-analysis of prospective cohort studies. *Br J Sports Med* 2008; **42**: 238–43.
- 21 Hamer M, Chida Y. Physical activity and risk of neurodegenerative disease: a systematic review of prospective evidence. *Psychol Med* 2009; **39**: 3–11.
- 22 Jeon CY, Lokken RP, Hu FB, van Dam RM. Physical Activity of Moderate Intensity and Risk of Type 2 Diabetes: A systematic review. *Diabetes Care* 2007; **30**: 744–52.
- 23 Kelly P, Kahlmeier S, Götschi T, *et al.* Systematic review and meta-analysis of reduction in all-cause mortality from walking and cycling and shape of dose response relationship. *Int J Behav Nutr Phys Act* 2014; **11**: 132.
- 24 Projections de population 2005-2050 pour la France métropolitaine. *Insee Résultats* 2006. https://www.insee.fr/fr/statistiques/2530035?sommaire=2530059.
- 25 Götschi T, Kahlmeier S, Castro A, *et al.* Integrated Impact Assessment of Active Travel: Expanding the Scope of the Health Economic Assessment Tool (HEAT) for Walking and Cycling. *Int J Environ Res Public Health* 2020; **17**: 7361.
- 26 Murray CJL, Aravkin AY, Zheng P, *et al.* Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. *The Lancet* 2020; **396**: 1223–49.
- 27 Dervaux B, Rochaix L, Meurisse B. L'évaluation socioéconomique des effets de santé des projets d'investissement public. France: CGDD, France Stratégie, SGPI, 2022 https://www.strategie.gouv.fr/publications/levaluation-socioeconomique-effets-de-sante-projetsdinvestissement-public-0 (accessed May 2, 2022).
- 28 Quinet E. Cost benefit assessment of public investments. Final Rep Summ Recomm Paris Fr CGSP Policy Plan Comm 2013. https://www.strategie.gouv.fr/sites/strategie.gouv.fr/files/archives/CGSP\_Evaluation\_socioeconomiq ue\_17092013.pdf.
- 29 Lumley T. survey: analysis of complex survey samples. 2020.
- 30 Rubin DB. Multiple imputation for nonresponse in surveys. John Wiley & Sons, 2004.
- 31 Leroutier M, Quirion P. Tackling car emissions in urban areas: Shift, Avoid, Improve. *SocArXiv* 2022. DOI:10.31235/osf.io/f5kmd.
- 32 Castro A, Kahlmeier S, Götschi T. Exposure-Adjusted Road Fatality Rates for Cycling and Walking in European Countries. ITF. 2018; published online Sept 25. https://www.itf-oecd.org/exposure-adjusted-road-fatality-rates-cycling-and-walking-european-countries (accessed Dec 13, 2022).
- 33 Center for Transport Analytics, Transport DTU. The Danish National Travel Survey (TU) Latest dataset. https://www.cta.man.dtu.dk/english/national-travel-survey/latest\_dataset (accessed Jan 14, 2022).

- 34 Rojas-Rueda D, de Nazelle A, Teixidó O, Nieuwenhuijsen MJ. Replacing car trips by increasing bike and public transport in the greater Barcelona metropolitan area: a health impact assessment study. *Environ Int* 2012; **49**: 100–9.
- 35 Ried-Larsen M, Rasmussen MG, Blond K, *et al.* Association of Cycling With All-Cause and Cardiovascular Disease Mortality Among Persons With Diabetes: The European Prospective Investigation Into Cancer and Nutrition (EPIC) Study. *JAMA Intern Med* 2021; **181**: 1196–205.
- 36 Department of Transport and Main Roads, Queensland Government. Cycling investment in Queensland. 2023. https://sc-tmrwcmgr-cd.azurewebsites.net/Travel-and-transport/Cycling/Cycling-investment-in-Queensland (accessed July 27, 2023).
- 37 Observatoire national interministériel de la sécurité routière (ONISR). Bilan 2020 de la sécurité routière. 2021 https://www.onisr.securite-routiere.gouv.fr/etat-de-l-insecurite-routiere/bilans-annuels-de-la-securite-routiere/bilan-2020-de-la-securite-routiere.
- 38 Fragnol L. Réduction des vitesses sur les routes Analyse coûts bénéfices. THEMA Anal Ministère Transit Écologique 2018. https://www.ecologiquesolidaire.gouv.fr/sites/default/files/Th%C3%A9ma%20-%20R%C3%A9duction%20des%20vitesses%20sur%20les%20routes.pdf.
- 39 Bonaldi C, Hill C. Alcohol-attributable mortality in France in 2015. *Bull Épidémiologique Hebd* 2019; : 97–108.
- 40 Domergue S, Vermont B. Étude d'impact du crédit d'impôt pour la transition énergétique (CITE). Commissariat général au développement durable, 2018.
- 41 Donaire-Gonzalez D, Nazelle A de, Cole-Hunter T, *et al.* The Added Benefit of Bicycle Commuting on the Regular Amount of Physical Activity Performed. *Am J Prev Med* 2015; **49**: 842–9.
- 42 Brondeel R, Wasfi R, Perchoux C, *et al.* Is older adults' physical activity during transport compensated during other activities? Comparing 4 study cohorts using GPS and accelerometer data. *J Transp Health* 2019; **12**: 229–36.
- 43 Zhao Y, Hu F, Feng Y, *et al.* Association of Cycling with Risk of All-Cause and Cardiovascular Disease Mortality: A Systematic Review and Dose–Response Meta-analysis of Prospective Cohort Studies. *Sports Med* 2021; **51**: 1439–48.
- 44 Barban P, De Nazelle A, Chatelin S, Quirion P, Jean K. Assessing the Health Benefits of Physical Activity Due to Active Commuting in a French Energy Transition Scenario. *Int J Public Health* 2022; **0**. DOI:10.3389/ijph.2022.1605012.
- 45 Jarrett J, Woodcock J, Griffiths UK, *et al.* Effect of increasing active travel in urban England and Wales on costs to the National Health Service. *Lancet Lond Engl* 2012; **379**: 2198–205.
- 46 Bouscasse H, Gabet S, Kerneis G, *et al.* Designing local air pollution policies focusing on mobility and heating to avoid a targeted number of pollution-related deaths: Forward and backward approaches combining air pollution modeling, health impact assessment and cost-benefit analysis. *Environ Int* 2021; **159**: 107030.

47 Kraus S, Koch N. Provisional COVID-19 infrastructure induces large, rapid increases in cycling. *Proc Natl Acad Sci U S A* 2021; **118**: e2024399118.

# Panel: Research in context

# Evidence before this study

We searched PubMed with the search equation (Bicycling[mesh] AND "health impact" and "physical activity") with no date restriction. The research returned 35 articles. We also screened the reference lists of relevant articles returned by our search to identify other potentially relevant papers. A large part of the article assessed the health impact associated with scenarios projecting increasing cycling, alone or in combination with other features (eg increased walking or public transport use) and at varying scales (cities, metropolitan areas, countries). Other studies assessed the impact of specific schemes such as bike-sharing systems. Two studies only were conducted in France, one assessing the health benefits of reaching net-zero emission targets in transportation and the other simulating the impact of an urban mobility plan on physical activity, without reporting impacts on morbidity or mortality. We found only two studies reporting the impact of cycling both in terms of mortality, morbidity and costs saved: one for the UK (Woodcock et al) and the other in Melbourne, Australia (Brown et al). Overall, evidence shows that cycling may generate important population health and health economic benefits, though their magnitude largely varied across contexts and/or scenarios considered.

#### Added value of this study

Based on pre-Covid nationally representative transportation data, we show that in a country of low- to moderate cycling culture such as France, cycling already generates important public health and health-related economic benefits, with an approximate annual 1,900 deaths and €5 billion of intangible costs averted. This corresponds to an approximate 1€ prevented for every km cycled. Currently, males are the main beneficiaries of cycling health benefits in France because they represent a large fraction of the cyclists.

Simulations based on individual transportation data shows that shifting only a quarter of short (<10km) car trips would yield approximatively a 3-fold increase in benefits, while also contributing to more balanced health benefits across genders and generating sizeable CO<sub>2</sub> emission reductions.


# Implication of all the available evidence

This study adds to the available evidence to show that cycling promotion policies would generate substantial public health benefits, which may be comparable to the gains expected by large-scale classical health prevention interventions, while also contributing to climate change mitigation targets.

**Table 1:** Data sources, medical costs, disability weights and dose-response functions used in the analysis to assess the health and health-related economic impact of physical activity.


Morbi- mortality event	Incidence data	Related Medical costs (per case)	Disability weight	RR, for 100 min cycling, ie 11.25 MET.hours (95% CI)	RR Reference
Breast Cancer (females)	National Cancer Institute	46,968€	0.068	0.90 (0.87-0.95)	Monninkhof et al., 2007
Colon Cancer	National Cancer Institute	26,716€	0.093	Males: 0.93 (0.88-0.99) Females: 0.94 (0.91-0.99)	Harris et al., 2009
Cardiovascular Disease	Long-term condition coverage	20,938€	0.052	0.92 (0.90-0.95)	Hamer & Chida, 2008
Dementia	Long-term condition coverage	22,748€	0.152	0.90 (0.86-0.95)	Hamer & Chida, 2009
Type 2 Diabetes	Long-term condition coverage	36,514 €	0.068	0.81 (0.72-0.89)	Jeon et al., 2007
All-cause mortality	INSEE	-	1	0.90 (0.87,.94)	Kelly et al., 2014

RR: Relative risk, CI: confidence interval. The relative risks for chronic diseases were those identify in a previous systematic review <sup>17</sup>. See Supplementary Table 1 for the initial values of RR, the references used for physical activity and the scaling for RR for 100min cycling.



**Figure 1**: Proportion of the French adult population reporting any bike trip any cycle trip a day, accounting for differences in weekends and weekdays (top), and mean distance cycled (km) in the past day among those reporting any bike trip (bottom) according to sex and age. *Enquête mobilité des personnes,* France, 2019.

Black lines represent 95% confidence intervals.




**Figure 2**: Chronic diseases and mortality prevented by the physical activity due to cycling in France among adults aged 20-89 years, 2019.


Black lines represent 95% uncertainty intervals.

**Table 2**: Burden, tangible costs and intangible costs prevented by the physical activity due to cycling in France, 2019, for several morbi-mortality event, among adults aged 20-89 years.

	Cases prevented in 2019 (Uncertainty	Medical (tangible) costs prevented in 2019, M€	Intangible costs prevented
Morbi-mortality event	interval, UI)	(UI)	in 2019,M€ (UI)
Breast cancer	254 (107-402)	11.9 (5.0-18.9)	58.2 (34.1-82.3)
Colon cancer	205 (51-359)	5.5 (1.4-9.6)	35.5 (14.3-56.6)
Cardiovascular disease	1578 (778-2378)	33.0 (16.3-49.8)	175.8 (113.6-238.0)
Dementia	182 (68-295)	4.1 (1.6-6.76)	29.1 (15.9-42.2)
Diabetes Type 2	3,744 (1,576-5,912)	136.76 (57.56-215.9)	723.3 (382.1-1064.6)
Mortality	1,919 (1,101-2,736)	Not Applicable	3731.8 (2808.2-4655.4)

Intangible costs are estimated based based on a value of a statistical life year (VSLY) of 133k€, expressed in Euros 2019.





DALY associated with chronic diseases correspond to years of life with disability (YLD) and DALY associated with mortality correspond to years of life lost (YLL, in blue).

Outcome	Baseline estimates (Uncertainty interval, UI)	Incremental effect of shifting 25% of short (<10km) car trips to cycling (in addition to the baseline estimates) (UI)
Yearly km cycled (billion)	4.640	5.550
	(3.284-5.996)	(4.222-6.884)
CO <sub>2</sub> emissions prevented (Mto)	0.575 (0.4070.743) 1	0.688
		(0.524-0.854)
# of deaths prevented	1919 (1101-2736)	4,704
		(2,689-6,721)
# of chronic diseases prevented	5,963 (3,178-8,749)	8,509
		(5,205-11,813)
# DALYS prevented	35,135 (22,693 – 48,791)	57,4650
		(34,983-78,733)
Direct medical (tangible) costs savings	191 (98-285)	267
(million €)		(178-393)
Intangible costs prevented	4.75 (3.02-6.49)	7.56
(billion €)		(4.65-14.47)
Intangible costs prevented for every km cycled (€)	1.02 (0.59-1.62)	-

**Table 3:** Climate, health and health-related economic benefits of cycling in France, 2019, and estimated impact of a modal shift scenario.

Intangible costs are estimated based on the value of a statistical life year (VSLY).

<sup>1</sup> As compared to a counterfactual where individual would have done the same trips driving instead of cycling

Dimension	Outcome	Value	Reference
Public health	Expected deaths yearly prevented by shifting 25% of short (<10km) car trips to bike	Approx 4,700 deaths yearly	Present study
	Deaths prevented by recent efforts for road safety over the past 10 years	Approx 1,500 deaths yearly	37
	Deaths prevented yearly by reducing alcohol consumption by 20%	Approx 1,500 deaths yearly	39
Economics	Expected medical (tangible) costs prevented by shifting 25% of short (<10km) car trips to bike	Approx. €270 million yearly	Present study
	Intangible costs prevented by shifting 25% of short (<10km) car trips to bike	Approx. €7,500 million yearly	Present study
	Yearly budget of the French National Cancer Institute (INCa)	€118.5 million in 2023	https://www.e- cancer.fr/Institut-national- du-cancer/Qui-sommes- nous/Budget
Climate change mitigation	CO <sub>2</sub> emissions prevented by shifting 25% of short (<10km) car trips to bike	Approx. 0.7 Mto yearly	Present study
	CO <sub>2</sub> emissions prevented by reducing the maximal speed on highway from 130 to 110 km/h	Approx. 1.45 Mto yearly	38
	Energy efficiency tax credit for households' investment in home thermal renovation	Approx. 0.12 Mto yearly in 2015 and 2016	40

Table 4: The public health, health-related economic and climate mitigation benefits of cycling in context, France


# Supplementary material

**Supplementary table 1:** Relative risks relating physical activity and several chronic diseases as identified in a previous systematic review (Rojas-Rueda et al, 2013).

Morbi- mortality event	Reference	RR (95% CI)	Unit	RR scaled for 100 min cycling, ie 11.25 MET.hours (95% CI)
Breast Cancer (women)	Monninkhof et al., 2007	0.94 (0.92, 0.97)	For each additional hour per week	0.90 (0.87-0.95)
Colon Cancer	Harris et al., 2009	Males: 0.80 (0.67, 0.96)	Men: Per 30,1 METs per week	Males: 0.93 (0.88-0.99) Females: 0.94 (0.91-
		Females: 0.86 (0.76, 0.98)	Women: Per 30,9 METs per week	0.99)
Cardiovascular Disease	Hamer & Chida, 2008	0.84 (0.79,0.90)	3 h per week of physical activity of moderate intensity	0.92 (0.90-0.95)
Dementia	Hamer & Chida, 2009	0.72 (0.60, 0.86)	33 METs per week	0.90 (0.86-0.95)
Type 2 Diabetes	Jeon et al., 2007	0.83 (0.75, 0.91)	Per 10 METs per week	0.81 (0.72-0.89)

RR: relative risk; CI: confidence interval.

The scaled RR was obtained using the formula:  $RR_{scaled} = 1 - (1 - RR_{ref})^* (11.25^* Unit_{ref})$ .



**Supplementary Figure 1**: Proportion of the French adult population reporting any short (<10km) car trip in the past day (top), and mean distance driven (km) in the past day among those reporting any car trip (down) according to sex and age. *Enquête mobilité des personnes,* France, 2019. Black lines represent 95% confidence intervals.